Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.
about
New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologistsFrom cardiac tissue engineering to heart-on-a-chip: beating challengesA cell-based biosensor for real-time detection of cardiotoxicity using lensfree imaging.Bioprinting 3D microfibrous scaffolds for engineering endothelialized myocardium and heart-on-a-chip.Functional dyspepsia.Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.Tegaserod mimics the neurostimulatory glycan polysialic acid and promotes nervous system repair.An optical multi-sensing system for detection of cardiovascular toxicity.Visceral pain hypersensitivity in functional gastrointestinal disorders.Human stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line.Additional safety risk to exceptionally approved drugs in Europe?Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.Does Timing of Colon Procedures Affect Outcomes in D-IBS Trials?Aptamer-Based Microfluidic Electrochemical Biosensor for Monitoring Cell-Secreted Trace Cardiac Biomarkers.Does Timing of Colon Procedures Affect Outcomes in D-IBS Trials?
P2860
Q26748617-5003CAB9-BF72-4F2C-9833-9C6F29E3EDCBQ27022144-356D9459-8F42-46EC-B7E3-D8229BB6953BQ30538150-09E6257E-14A7-4EC8-89D7-29DD9376D102Q30833397-77F48334-D234-41CA-8538-A4170FA6FE57Q34409166-CA94A5DA-4BC9-43CC-9C8A-124B798031F0Q34409219-99954D68-32F6-4517-979F-B5832FBB217AQ34997967-3C671AFF-BC11-46C6-A2A7-4D6181C2F661Q35101016-E80AE8FA-090F-475F-AAC9-12F0BD990331Q37557017-22430BE7-FCA8-4517-9A3B-89CAFA8A6B1DQ38240972-A17E121D-9E2B-4865-8DF2-CE40BA1334A4Q38504869-927C093B-3814-4BCB-9B4A-BA6DF87AF447Q43171523-EE2E0080-B158-4AD3-99B5-E2E9885E8004Q49520160-EAFD7B3D-D558-4450-810A-4C8F6A4CE1A3Q51166866-E7CE3F69-77FC-4B5B-A560-0080BCCE2413Q53456521-60DEAC61-7254-41B0-9056-61E251C11C01
P2860
Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Balancing drug risk and benefi ...... isions affecting patient care.
@en
Balancing drug risk and benefi ...... isions affecting patient care.
@nl
type
label
Balancing drug risk and benefi ...... isions affecting patient care.
@en
Balancing drug risk and benefi ...... isions affecting patient care.
@nl
prefLabel
Balancing drug risk and benefi ...... isions affecting patient care.
@en
Balancing drug risk and benefi ...... isions affecting patient care.
@nl
P2860
P1476
Balancing drug risk and benefi ...... isions affecting patient care.
@en
P2093
David A Johnson
Lawrence R Schiller
P2860
P304
P356
10.1111/J.1572-0241.2008.01818.X
P407
P577
2008-04-01T00:00:00Z